PubMed HealthSearch

Biomedical subjects

F Macrae

Publications and source records attributed to F Macrae.

8 recordsLinked to original sources

Epidemiology and early detection of colorectal cancer.

Further information consolidating the roles of dietary fat and fiber and physical inactivity in colorectal carcinogenesis has been published in the year under review. A large cohort study identified animal fat as the most important dietary risk factor, and a meta-analysis of fiber supported the role particularly of vegetable fiber in protection. An important population-based study in Scandinavia identified age at onset of ulcerative colitis as a factor independent of length of follow-up; risk at 35 years after onset was 40% for those with early-stage onset. An update at the St. Mark's Hospital, London, surveillance experience offers measured support for endoscopic screening for dysplasia and curable cancer. A unique paper from Japan defines a relative risk of cancer after polypectomy of 2.3. A case-control study of occult blood screening showed that the sensitivity of guaiac testing for fecal occult blood (Hemoccult, Smith Kline Diagnostics, CA) for asymptomatic colorectal cancer is just under 50%. Cost-benefit modeling suggests that annual occult blood testing and 3- to 5-yearly flexible sigmoidoscopy are optimal.

Colorectal Neoplasms

Hemoccult tests.

Explore the source record for details and available documents.

False Positive Reactions

Surveillance and early diagnosis of colorectal cancer.

Colorectal cancer is a major health problem in western countries such as the United States. The annual incidence of more than 130,000 new cases, and the annual mortality of more than 60,000 people justifies a consideration of efforts for its control. New concepts of risk, better understanding of the adenoma-adenocarcinoma natural history, and new screening and diagnostic technology have provided a basis for possible preventive approaches. Trials are in progress evaluating the fecal occult blood test and sigmoidoscopy screening tests, and colonoscopy as a diagnostic and surveillance test. Evaluation of data from the trials requires many considerations regarding bias and validity. Although the data from screening trials appear to be promising, they are still preliminary. In the interim, guidelines have been proposed for screening strategies related to average risk and high risk groups. Considerably more work will be required in order to provide the scientific basis for the control of large bowel cancer. In addition, efforts will have to be directed toward the effective communication of new concepts, data and techniques to the majority of physicians who interact with the at-risk population. Efforts will also have to be directed to the public at large to enhance their compliance with the approaches to increase their awareness of colorectal cancer as an important disease and to eliminate their misconceptions. Finally the cost effectiveness of various screening strategies will have to be examined once data indicates a benefit of such approaches.

Clinical Trials as Topic